Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kezar Life Sciences
Biotech
FDA hits Kezar's zetomipzomib with 2nd clinical hold in 2 months
The FDA has placed a partial hold on the PORTOLA trial evaluating the selective immunoproteasome inhibitor in 24 patients with autoimmune hepatitis.
James Waldron
Nov 13, 2024 5:22am
Kezar rejects Concentra buyout that 'undervalues' the biotech
Oct 17, 2024 9:10am
With Kezar in lupus limbo, Concentra spies potential acquisition
Oct 9, 2024 7:10am
FDA places Kezar lupus trial in hold following 4 patient deaths
Oct 7, 2024 5:50am
Kezar suspends key lupus study after 4 deaths
Sep 30, 2024 11:23am
Kezar drops solid tumor yet to prove its worth in phase 1 trial
Aug 14, 2024 5:09am
